These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25351173)

  • 61. Dosimetric comparison of interactive planned and dynamic dose calculated prostate seed brachytherapy.
    Meijer GJ; van den Berg HA; Hurkmans CW; Stijns PE; Weterings JH
    Radiother Oncol; 2006 Sep; 80(3):378-84. PubMed ID: 16930753
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
    Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
    Kassim I; Dirkx ML; Heijmen BJ
    Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
    Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
    Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.
    Sahgal A; Jabbari S; Chen J; Pickett B; Roach M; Weinberg V; Hsu IC; Pouliot J
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):247-54. PubMed ID: 18722275
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
    Potters L; Calugaru E; Jassal A; Presser J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High-risk CTV delineation for cervix brachytherapy: Application of GEC-ESTRO guidelines in Australia and New Zealand.
    Vinod SK; Lim K; Bell L; Veera J; Ohanessian L; Juresic E; Borok N; Chan P; Chee R; Do V; Govindarajulu G; Sridharan S; Johnson C; Moses D; Van Dyk S; Holloway L
    J Med Imaging Radiat Oncol; 2017 Feb; 61(1):133-140. PubMed ID: 27527506
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.
    Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
    Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Dosimetric evaluation of interstitial high-dose-rate implants for localised prostate cancer].
    Fröhlich G; Agoston P; Lövey J; Somogyi A; Fodor J; Major T
    Magy Onkol; 2007; 51(1):31-8. PubMed ID: 17417673
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125.
    Bloemen-van Gurp EJ; Haanstra BK; Murrer LH; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1266-72. PubMed ID: 19665317
    [TBL] [Abstract][Full Text] [Related]  

  • 72. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
    Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
    Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds.
    McLaughlin P; Narayana V; Pan C; Berri S; Troyer S; Herman J; Evans V; Roberson P
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):144-50. PubMed ID: 16243441
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
    Rijkhorst EJ; Lakeman A; Nijkamp J; de Bois J; van Herk M; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1254-60. PubMed ID: 19857789
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
    Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
    Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
    Dicker AP; Lin CC; Leeper DB; Waterman FM
    Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
    [TBL] [Abstract][Full Text] [Related]  

  • 77. What is the dosimetric impact of isotropic vs anisotropic safety margins for delineation of the clinical target volume in breast brachytherapy?
    Kumar A; Wadasadawala T; Joshi K; Pathak R; Scaria L; Upreti RR; Bhajbhuje R; Shet T; Parmar V; Gupta S; Mokal S; Sarin R
    Brachytherapy; 2021; 20(1):155-162. PubMed ID: 32888852
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is there a preferred strength for regularly spaced 125I seeds in inverse-planned prostate implants?
    Sloboda RS; Pedersen JE; Halperin R
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):234-44. PubMed ID: 12504058
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Permanent LDR prostate brachytherapy: Comprehensive characterization of seed-dynamics within the prostate on a seed-only level.
    Karius A; Lotter M; Kreppner S; Schaller V; Lubgan D; Grigo J; Fietkau R; Strnad V; Bert C
    Brachytherapy; 2022; 21(5):635-646. PubMed ID: 35643593
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Monte Carlo study of I-125 prostate brachytherapy with gold nanoparticles: dose enhancement with simultaneous rectal dose sparing via radiation shielding.
    Brivio D; Nguyen PL; Sajo E; Ngwa W; Zygmanski P
    Phys Med Biol; 2017 Mar; 62(5):1935-1948. PubMed ID: 28140338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.